IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT05304585 pour Rhabdomyosarcome Embryonnaire, Fusion-negative Alveolar Rhabdomyosarcoma, Rhabdomyosarcome à cellules fusiformes/sclérose est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'essai clinique NCT05304585 est conçu pour étudier le treatment de Rhabdomyosarcome Embryonnaire, Fusion-negative Alveolar Rhabdomyosarcoma, Rhabdomyosarcome à cellules fusiformes/sclérose. Il s'agit d'un essai interventionnel en Phase III. Son statut actuel est : en recrutement. L'essai a débuté le 4 août 2022 et vise à recruter 205 participants. Dirigé par Children's Oncology Group, l'essai devrait être terminé d'ici le 30 juin 2030. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 24 octobre 2025.
Résumé succinct
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-RMS) respond to standard chemotherapy when patients with VLR-RMS and patients who have rhabdomyosarcoma with DNA mutations get separate treatment. Finally, this study examines the effect of therapy intensification in patients who have RMS cancer with DNA mutations to see if their outcomes can be improved.
Description détaillée
PRIMARY OBJECTIVES:
I. To evaluate the failure free survival (FFS) of patients with very low-risk (VLR) rhabdomyosarcoma (RMS) (fusion negative [FN], stage 1, clinical group [CG] I, MYOD1 wildtype [WT], TP53 [WT]) when treated with 24 weeks of vincristine and dactinomycin (VA).
II. To evaluate the FFS of patients with low-risk (LR) RMS (FN, stage 1 CG II, or stage 2 CG I/II or CG III [orbit only], MYOD1 WT, TP53 WT) when treated with 12 weeks of vincristine, dactinomycin and cyclophosphamide (VAC) followed by 12 weeks of VA.
SECONDARY OBJECTIVES:
I. To evaluate the overall survival (OS) of patients with VLR RMS treated with 24 weeks of VA.
II. To evaluate the OS of patients with LR RMS treated with 12 weeks of VAC followed by 12 weeks of VA.
III. To demonstrate the feasibility of central molecular risk stratification of patients with newly diagnosed RMS in the context of a prospective clinical trial.
EXPLORATORY OBJECTIVES:
I. To collect blood and tissue samples for banking at baseline, during treatment, at the end of therapy, and at the time of progression to bank for future research.
II. To describe the methylation array profile of patients with fusion negative, low-risk rhabdomyosarcoma.
III. To describe the outcomes of patients with VLR or LR RMS and MYOD1 or TP53 mutations treated with intensified therapy.
OUTLINE: Patients are assigned to 1 of 2 regimens based on clinical features. Patients with positive mutation status are transitioned to a third regimen, Regimen M.
REGIMEN VA: Patients with VLR RMS receive vincristine intravenously (IV) on day 1 of each cycle and days 8 and 15 of cycles 1, 3, 5, and 7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3).
REGIMEN VAC/VA: Patients with LR RMS receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 1-3. Patients also receive dactinomycin IV over 1-5 minutes or 10-15 minutes and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 5-7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3). Patients may also undergo radiation therapy at cycle 5.
REGIMEN M: Patients receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 2-4, 7-8, and 11-12 and dactinomycin IV over 1-5 minutes or 10-15 minutes on day 1 of cycles 2-5 and 8-14. Patients also receive cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 12-13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo radiation therapy at cycle 5.
Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI), bone scan, positron emission tomography (PET) scan and tumor biopsy throughout the study.
Titre officiel
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
Conditions
Rhabdomyosarcome EmbryonnaireFusion-negative Alveolar RhabdomyosarcomaRhabdomyosarcome à cellules fusiformes/scléroseAutres identifiants de l'essai
- ARST2032
- NCI-2022-01012 (Identifiant de registre) (CTRP (Clinical Trial Reporting Program))
- ARST2032 (Autre Identifiant) (Children's Oncology Group)
- ARST2032 (Autre Identifiant) (CTEP)
- U10CA180886 (Subvention/contrat NIH (É.-U.))
Numéro NCT
Date de début (réel)
2022-08-04
Dernière mise à jour publiée
2025-10-24
Date de fin (estimée)
2030-06-30
Inscription (estimée)
205
Type d'essai
Interventionnel
PHASE
Phase III
Statut
En recrutement
Objectif principal
Traitement
Plan d'attribution
Non aléatoire
Modèle d'intervention
Parallèle
Masquage
Aucun (ouvert)
Bras / Interventions
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
ExpérimentalRegimen M (positive mutation) Patients receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 2-4, 7-8, and 11-12 and dactinomycin IV over 1-5 minutes or 10-15 minutes on day 1 of cycles 2-5 and 8-14. Patients also receive cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 12-13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo radiation therapy at cycle 5. Patients undergo CT scan, MRI, bone scan, PET scan and tumor biopsy throughout the study. | Biopsy Procedure Undergo tumor biopsy Scintigraphie osseuse Undergo bone scan Tomodensitométrie Undergo CT scan Cyclophosphamide Given IV Dactinomycin Given IV Élastographie par résonance magnétique Undergo MRI Tomographie par émission de positrons Undergo PET scan Thérapie par radiation Undergo radiation Vincristine Given IV |
ExpérimentalRegimen VA (VLR RMS) Patients with VLR RMS receive vincristine intravenously (IV) on day 1 of each cycle and days 8 and 15 of cycles 1, 3, 5, and 7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3). Patients undergo CT scan, MRI, bone scan, PET scan and tumor biopsy throughout the study. | Biopsy Procedure Undergo tumor biopsy Scintigraphie osseuse Undergo bone scan Dactinomycin Given IV Élastographie par résonance magnétique Undergo MRI Tomographie par émission de positrons Undergo PET scan Vincristine Given IV |
ExpérimentalRegimen VAC/VA (VL RMS) Patients with LR RMS receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 1-3. Patients also receive dactinomycin IV over 1-5 minutes or 10-15 minutes and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 5-7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3). Radiation therapy (if needed) will be administered at cycle 5.Patients undergo CT scan, MRI, bone scan, PET scan and tumor biopsy throughout the study. | Biopsy Procedure Undergo tumor biopsy Scintigraphie osseuse Undergo bone scan Tomodensitométrie Undergo CT scan Cyclophosphamide Given IV Dactinomycin Given IV Élastographie par résonance magnétique Undergo MRI Tomographie par émission de positrons Undergo PET scan Vincristine Given IV |
Critère principal d'évaluation
Critère secondaire d'évaluation
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Failure free survival (FFS) for very low risk patients | The Kaplan-Meier method will be used to estimate 3-year FFS along with 80% log-minus-log transformed confidence limits for very low risk (VLR) patients. | From study enrollment to disease progression, recurrence, or death as a first event, assessed up to 3 years |
Failure free survival (FFS) for low risk patients | The Kaplan-Meier method will be used to estimate 3 year FFS along with 80% log-minus-log transformed confidence limits for low risk (LR) patients. | From study enrollment to disease progression, recurrence, or death as a first event, assessed up to 3 years |
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
Overall survival (OS) for very low risk patients | Log-rank test will be used to compare the OS of patients with VLR rhabdomyosarcoma (RMS) treated with 24 weeks of vincristine, dactinomycin (VA) to the VLR RMS patients from ARST0331 and D9602 with the same inclusion criteria. | From study entry to death of any cause, assessed up to 5 years |
Overall survival (OS) for low risk patients | Log-rank test will be used to compare the OS from LR RMS patients to LR RMS patients from ARST0331 and D9602 with the same inclusion criteria. | From study entry to death of any cause, assessed up to 5 years |
Feasibility of central molecular risk stratification of patients assessed by the percentage of patients who have molecular testing results returned by 6 weeks | If the percentage of patients who have molecular testing results returned by 6 weeks is \>= 80% then the central molecular risk stratification is considered feasible. | Up to 24 weeks |
Critères d'éligibilité
Âges éligibles
Enfant, Adulte
Sexes éligibles
Tous
All patients must be enrolled on APEC14B1 (NCT02402244) and consented to the Molecular Characterization Initiative (Part A) prior to enrollment and treatment on ARST2032 (this trial).
Patients must be =< 21 years at the time of enrollment.
Patients must have newly diagnosed embryonal rhabdomyosarcoma (ERMS), spindle cell/sclerosing RMS, or FOXO1 fusion negative alveolar rhabdomyosarcoma (ARMS) (institutional FOXO1 fusion results are acceptable). RMS types included under ERMS include those classified in the 1995 International Classification of Rhabdomyosarcoma (ICR) as ERMS (classic, spindle cell, and botryoid variants), which are reclassified in the 2020 World Health Organization (WHO) classification as ERMS (classic, dense and botryoid variants) and spindle cell/sclerosing RMS (encompassing the historical spindle cell ERMS variant and the newly recognized sclerosing RMS variant). Enrollment in APEC14B1 is required for all patients.
All patients will be evaluated for stage and clinical group. Note that clinical group designation assigned at the time of enrollment on study remains unchanged regardless of any second-look operation that may be performed.
- Patients will be eligible for the very low-risk stratum (Regimen VA) if they have Stage 1, CG I disease.
- Patients will be eligible for the low-risk stratum (Regimen VAC/VA) if they have Stage 1, CG II disease, Stage 2, CG I or II disease, or Stage 1, CG III (orbit only) disease.
Paratesticular Tumors: Staging ipsilateral retroperitoneal lymph node sampling (SIRLNS) is required for all patients >= 10 years of age with paratesticular tumors who do not have gross nodal involvement on imaging.
Extremity Tumors: Regional lymph node sampling is required for histologic evaluation in patients with extremity tumors.
Clinically or radiographically enlarged nodes must be sampled for histologic evaluation.
Patients must have a Lansky (for patients =< 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of >= 50. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing performance score.
Peripheral absolute neutrophil count (ANC) >= 750/uL (within 7 days prior to enrollment).
Platelet count >= 75,000/uL (transfusion independent) (within 7 days prior to enrollment).
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine (within 7 days prior to enrollment) based on age/gender as follows:
- Age: 1 month to < 6 months; Maximum serum creatinine (mg/dL): 0.4 (male) : 0.4 (female)
- Age: 6 months to < 1 year; Maximum serum creatinine (mg/dL): 0.5 (male) : 0.5 (female)
- Age: 1 to < 2 years; Maximum serum creatinine (mg/dL): 0.6 (male) : 0.6 (female)
- Age: 2 to < 6 years; Maximum serum creatinine (mg/dL): 0.8 (male) : 0.8 (female)
- Age: 6 to < 10 years; Maximum serum creatinine (mg/dL): 1 (male) : 1 (female)
- Age: 10 to < 13 years; Maximum serum creatinine (mg/dL): 1.2 (male) : 1.2 (female)
- Age: 13 to < 16 years; Maximum serum creatinine (mg/dL): 1.5 (male) : 1.4 (female)
- Age >= 16 years; Maximum serum creatinine (mg/dL): 1.7 (male) : 1.4 (female)
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment), and
- If there is evidence of biliary obstruction by the tumor, then the total bilirubin must be < 3 x ULN for age.
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L.
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L
- If there is evidence of biliary obstruction by the tumor, then the total bilirubin must be < 3 x ULN for age
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
All patients and/or their parents or legal guardians must sign a written informed consent.
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.
- Patients who have received prior chemotherapy and/or radiation therapy for cancer prior to enrollment. Surgical resection alone of previous cancer(s) is permitted.
- Patients who have received chemotherapy or radiation for non-malignant conditions (e.g., autoimmune diseases) are eligible. Patients must discontinue chemotherapy for non-malignant conditions prior to starting protocol therapy.
- Vincristine is sensitive substrate of the CYP450 3A4 isozyme. Patients must not have received drugs that are moderate to strong CYP3A4 inhibitors and inducers within 7 days prior to study enrollment.
- Patients unable to undergo radiation therapy, if necessary, as specified in the protocol.
- Evidence of uncontrolled infection.
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential.
- Lactating females who plan to breastfeed their infants.
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation.
Children's Oncology GroupInstitut national du cancer, États-Unis3028 essais cliniques actifs à explorerAucune donnée de contact disponible
177 Centres de l'essai dans 4 pays
Alberta
Alberta Children's Hospital, Calgary, Alberta, T3B 6A8, Canada
Site Public Contact, Contact, 403-220-6898, [email protected]
Victor A. Lewis, Investigateur principal
En recrutement
University of Alberta Hospital, Edmonton, Alberta, T6G 2B7, Canada
Site Public Contact, Contact, 780-407-8798, [email protected]
Sarah J. McKillop, Investigateur principal
En recrutement
British Columbia
British Columbia Children's Hospital, Vancouver, British Columbia, V6H 3V4, Canada
Site Public Contact, Contact, 604-875-2345
Rebecca J. Deyell, Investigateur principal
En recrutement
Manitoba
CancerCare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada
Site Public Contact, Contact, 866-561-1026, [email protected]
Stephanie M. Villeneuve, Investigateur principal
En recrutement
Nova Scotia
IWK Health Centre, Halifax, Nova Scotia, B3K 6R8, Canada
Site Public Contact, Contact, 902-470-8520, [email protected]
Craig Erker, Investigateur principal
En recrutement
Ontario
Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada
Site Public Contact, Contact, 416-813-7654, [email protected]
Anita Villani, Investigateur principal
En recrutement
Quebec
The Montreal Children's Hospital of the MUHC, Montreal, Quebec, H3H 1P3, Canada
Site Public Contact, Contact, 514-412-4445, [email protected]
Stephanie Mourad, Investigateur principal
En recrutement
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, H3T 1C5, Canada
Site Public Contact, Contact, 514-345-4931, [email protected]
Monia Marzouki, Investigateur principal
En recrutement
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke, Quebec, J1H 5N4, Canada
Site Public Contact, Contact, 819-820-6480, [email protected]
Josee Brossard, Investigateur principal
En recrutement
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Québec, G1V 4G2, Canada
Site Public Contact, Contact, 418-525-4444, [email protected]
Bruno Michon, Investigateur principal
En recrutement
Alabama
Children's Hospital of Alabama, Birmingham, Alabama, 35233, United States
Site Public Contact, Contact, 205-638-9285, [email protected]
Jamie M. Aye, Investigateur principal
En recrutement
USA Health Strada Patient Care Center, Mobile, Alabama, 36604, United States
Site Public Contact, Contact, 800-388-8721
Hamayun Imran, Investigateur principal
En recrutement
Arizona
Phoenix Childrens Hospital, Phoenix, Arizona, 85016, United States
Site Public Contact, Contact, 602-546-0920
Nawal Merjaneh, Investigateur principal
En recrutement
Arkansas
Arkansas Children's Hospital, Little Rock, Arkansas, 72202-3591, United States
Site Public Contact, Contact, 501-364-7373
David L. Becton, Investigateur principal
En recrutement
California
Kaiser Permanente Downey Medical Center, Downey, California, 90242, United States
Site Public Contact, Contact, 626-564-3455
Robert M. Cooper, Investigateur principal
En recrutement
Loma Linda University Medical Center, Loma Linda, California, 92354, United States
Site Public Contact, Contact, 909-558-4050
Albert Kheradpour, Investigateur principal
En recrutement
Miller Children's and Women's Hospital Long Beach, Long Beach, California, 90806, United States
Site Public Contact, Contact, 562-933-5600
Jacqueline N. Casillas, Investigateur principal
En recrutement
Children's Hospital Los Angeles, Los Angeles, California, 90027, United States
Site Public Contact, Contact, 323-361-4110
Sara Kreimer, Investigateur principal
En recrutement
Cedars Sinai Medical Center, Los Angeles, California, 90048, United States
Site Public Contact, Contact, 310-423-8965
Leo Mascarenhas, Investigateur principal
En recrutement
Mattel Children's Hospital UCLA, Los Angeles, California, 90095, United States
Site Public Contact, Contact, 310-825-6708
Noah C. Federman, Investigateur principal
En recrutement
Valley Children's Hospital, Madera, California, 93636, United States
Site Public Contact, Contact, 559-353-3000, [email protected]
Ruetima Titapiwatanakun, Investigateur principal
En recrutement
UCSF Benioff Children's Hospital Oakland, Oakland, California, 94609, United States
Site Public Contact, Contact, 510-428-3264, [email protected]
Jennifer G. Michlitsch, Investigateur principal
En recrutement
Kaiser Permanente-Oakland, Oakland, California, 94611, United States
Site Public Contact, Contact, 877-642-4691, [email protected]
Aarati V. Rao, Investigateur principal
En recrutement
Children's Hospital of Orange County, Orange, California, 92868, United States
Site Public Contact, Contact, 714-509-8646, [email protected]
Elyssa M. Rubin, Investigateur principal
En recrutement
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, 94304, United States
Site Public Contact, Contact, 800-694-0012, [email protected]
Jay Michael S. Balagtas, Investigateur principal
En recrutement
Rady Children's Hospital - San Diego, San Diego, California, 92123, United States
Site Public Contact, Contact, 858-966-5934
William D. Roberts, Investigateur principal
En recrutement
Naval Medical Center -San Diego, San Diego, California, 92134, United States
Site Public Contact, Contact, 619-532-8712
Yoko T. Udaka, Investigateur principal
En recrutement
UCSF Medical Center-Mission Bay, San Francisco, California, 94158, United States
Site Public Contact, Contact, 877-827-3222, [email protected]
Arun A. Rangaswami, Investigateur principal
En recrutement
Colorado
Children's Hospital Colorado, Aurora, Colorado, 80045, United States
Site Public Contact, Contact, 303-764-5056, [email protected]
Masanori Hayashi, Investigateur principal
En recrutement
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, 80218, United States
Site Public Contact, Contact, 303-832-2344, [email protected]
Florence Choo, Investigateur principal
En recrutement
Connecticut
Connecticut Children's Medical Center, Hartford, Connecticut, 06106, United States
Site Public Contact, Contact, 860-545-9981
Michael S. Isakoff, Investigateur principal
En recrutement
Yale University, New Haven, Connecticut, 06520, United States
Site Public Contact, Contact, 203-785-5702, [email protected]
Farzana Pashankar, Investigateur principal
En recrutement
Delaware
Alfred I duPont Hospital for Children, Wilmington, Delaware, 19803, United States
Site Public Contact, Contact, 302-651-5572, [email protected]
Scott M. Bradfield, Investigateur principal
En recrutement
District of Columbia
MedStar Georgetown University Hospital, Washington D.C., District of Columbia, 20007, United States
Site Public Contact, Contact, 202-444-2223
Caileigh Pudela, Investigateur principal
En recrutement
Children's National Medical Center, Washington D.C., District of Columbia, 20010, United States
Site Public Contact, Contact, 202-476-2800, [email protected]
Jeffrey S. Dome, Investigateur principal
En recrutement
Florida
Broward Health Medical Center, Fort Lauderdale, Florida, 33316, United States
Site Public Contact, Contact, 302-651-5572, [email protected]
Hector M. Rodriguez-Cortes, Investigateur principal
En recrutement
Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, 33908, United States
Site Public Contact, Contact, 239-343-5333, [email protected]
Emad K. Salman, Investigateur principal
En recrutement
University of Florida Health Science Center - Gainesville, Gainesville, Florida, 32610, United States
Site Public Contact, Contact, 352-273-8010, [email protected]
Brian Stover, Investigateur principal
En recrutement
Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, 33021, United States
Site Public Contact, Contact, 954-265-1847, [email protected]
Iftikhar Hanif, Investigateur principal
En recrutement
Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, 32207, United States
Site Public Contact, Contact, 302-651-5572, [email protected]
Scott M. Bradfield, Investigateur principal
En recrutement
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, 33136, United States
Site Public Contact, Contact, 305-243-2647
Aditi Dhir, Investigateur principal
En recrutement
Nicklaus Children's Hospital, Miami, Florida, 33155, United States
Site Public Contact, Contact, 888-624-2778
Maggie E. Fader, Investigateur principal
En recrutement
AdventHealth Orlando, Orlando, Florida, 32803, United States
Site Public Contact, Contact, 407-303-2090, [email protected]
Fouad M. Hajjar, Investigateur principal
En recrutement
Arnold Palmer Hospital for Children, Orlando, Florida, 32806, United States
Site Public Contact, Contact, 321-841-5357, [email protected]
Jaime M. Libes-Bander, Investigateur principal
En recrutement
Nemours Children's Hospital, Orlando, Florida, 32827, United States
Site Public Contact, Contact, 302-651-5572, [email protected]
Scott M. Bradfield, Investigateur principal
En recrutement
Nemours Children's Clinic - Pensacola, Pensacola, Florida, 32504, United States
Site Public Contact, Contact, [email protected]
Jeffrey H. Schwartz, Investigateur principal
En recrutement
Sacred Heart Hospital, Pensacola, Florida, 32504, United States
Suspendu
Johns Hopkins All Children's Hospital, St. Petersburg, Florida, 33701, United States
Site Public Contact, Contact, 727-767-4784, [email protected]
Jennifer B. Dean, Investigateur principal
En recrutement
Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, 33607, United States
Site Public Contact, Contact, 813-357-0849, [email protected]
Don E. Eslin, Investigateur principal
En recrutement
Saint Mary's Medical Center, West Palm Beach, Florida, 33407, United States
Site Public Contact, Contact, 561-822-4745
Matthew D. Ramirez, Investigateur principal
En recrutement
Georgia
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, 30329, United States
Site Public Contact, Contact, 404-785-0232, [email protected]
Claire Stokes, Investigateur principal
En recrutement
Atrium Health Navicent, Macon, Georgia, 31201, United States
Site Public Contact, Contact, 478-633-2152, [email protected]
Sushmita Nair, Investigateur principal
En recrutement
Memorial Health University Medical Center, Savannah, Georgia, 31404, United States
Site Public Contact, Contact, 912-350-7887, [email protected]
Andrew L. Pendleton, Investigateur principal
En recrutement
Hawaii
Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, 96826, United States
Site Public Contact, Contact, 808-983-6090
Wade T. Kyono, Investigateur principal
En recrutement
Idaho
Saint Luke's Cancer Institute - Boise, Boise, Idaho, 83712, United States
Site Public Contact, Contact, 208-381-2774, [email protected]
Martha M. Pacheco, Investigateur principal
En recrutement
Illinois
Lurie Children's Hospital-Chicago, Chicago, Illinois, 60611, United States
Site Public Contact, Contact, 773-880-4562
Jennifer L. Reichek, Investigateur principal
En recrutement
University of Illinois, Chicago, Illinois, 60612, United States
Suspendu
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States
Site Public Contact, Contact, 773-702-8222, [email protected]
Ami V. Desai, Investigateur principal
En recrutement
Loyola University Medical Center, Maywood, Illinois, 60153, United States
Site Public Contact, Contact, 708-226-4357
Eugene Suh, Investigateur principal
En recrutement
Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, 60453, United States
Site Public Contact, Contact, 847-723-7570
Rebecca E. McFall, Investigateur principal
En recrutement
Advocate Children's Hospital-Park Ridge, Park Ridge, Illinois, 60068, United States
Site Public Contact, Contact, [email protected]
Rebecca E. McFall, Investigateur principal
En recrutement
Saint Jude Midwest Affiliate, Peoria, Illinois, 61637, United States
Site Public Contact, Contact, 888-226-4343
Prerna Kumar, Investigateur principal
En recrutement
Southern Illinois University School of Medicine, Springfield, Illinois, 62702, United States
Site Public Contact, Contact, 217-545-7929
Gregory P. Brandt, Investigateur principal
En recrutement
Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, 60190, United States
Site Public Contact, Contact, 630-315-1918, [email protected]
Jennifer L. Reichek, Investigateur principal
En recrutement
Indiana
Riley Hospital for Children, Indianapolis, Indiana, 46202, United States
Site Public Contact, Contact, 800-248-1199
Sandeep Batra, Investigateur principal
En recrutement
Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana, 46260, United States
Site Public Contact, Contact, 317-338-2194, [email protected]
Bassem I. Razzouk, Investigateur principal
En recrutement
Iowa
Blank Children's Hospital, Des Moines, Iowa, 50309, United States
Site Public Contact, Contact, 515-241-8912, [email protected]
Samantha L. Mallory, Investigateur principal
En recrutement
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242, United States
Site Public Contact, Contact, 800-237-1225
David S. Dickens, Investigateur principal
En recrutement
Kansas
Wesley Medical Center, Wichita, Kansas, 67214, United States
Site Public Contact, Contact, 316-962-7802, [email protected]
Nathan S. Hall, Investigateur principal
En recrutement
Kentucky
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, 40536, United States
Site Public Contact, Contact, 859-257-3379
James T. Badgett, Investigateur principal
En recrutement
Norton Children's Hospital, Louisville, Kentucky, 40202, United States
Site Public Contact, Contact, 502-629-5500, [email protected]
Michael J. Ferguson, Investigateur principal
En recrutement
Louisiana
Children's Hospital New Orleans, New Orleans, Louisiana, 70118, United States
Site Public Contact, Contact, 504-894-5377
Maria C. Velez-Yanguas, Investigateur principal
En recrutement
Ochsner Medical Center Jefferson, New Orleans, Louisiana, 70121, United States
Site Public Contact, Contact, 504-842-8084, [email protected]
Craig Lotterman, Investigateur principal
En recrutement
Maine
Maine Children's Cancer Program, Scarborough, Maine, 04074, United States
Site Public Contact, Contact, 207-396-8670, [email protected]
Aaron R. Weiss, Investigateur principal
En recrutement
Maryland
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, 21201, United States
Site Public Contact, Contact, 800-888-8823
Teresa A. York, Investigateur principal
En recrutement
Sinai Hospital of Baltimore, Baltimore, Maryland, 21215, United States
Site Public Contact, Contact, 410-601-9083
Jason M. Fixler, Investigateur principal
En recrutement
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States
Site Public Contact, Contact, 410-955-8804, [email protected]
Christine A. Pratilas, Investigateur principal
En recrutement
Massachusetts
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States
Site Public Contact, Contact, 877-726-5130
Alison M. Friedmann, Investigateur principal
En recrutement
Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States
Site Public Contact, Contact, 877-442-3324
Natalie B. Collins, Investigateur principal
En recrutement
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, 01655, United States
Site Public Contact, Contact, 508-856-3216, [email protected]
Stefanie R. Lowas, Investigateur principal
En recrutement
Michigan
C S Mott Children's Hospital, Ann Arbor, Michigan, 48109, United States
Site Public Contact, Contact, 800-865-1125
Rama Jasty, Investigateur principal
En recrutement
Children's Hospital of Michigan, Detroit, Michigan, 48201, United States
Site Public Contact, Contact, [email protected]
Alissa M. Martin, Investigateur principal
En recrutement
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, 49503, United States
Site Public Contact, Contact, 616-391-1230, [email protected]
Kathleen Y. Butler, Investigateur principal
En recrutement
Bronson Methodist Hospital, Kalamazoo, Michigan, 49007, United States
Site Public Contact, Contact, 616-391-1230, [email protected]
Kathleen Y. Butler, Investigateur principal
En recrutement
Corewell Health Children's, Royal Oak, Michigan, 48073, United States
Site Public Contact, Contact, 248-551-7695
Marie V. Nelson, Investigateur principal
En recrutement
Minnesota
Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, 55404, United States
Site Public Contact, Contact, 612-813-5913, [email protected]
Michael K. Richards, Investigateur principal
En recrutement
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, 55455, United States
Site Public Contact, Contact, 612-624-2620
Robin L. Williams, Investigateur principal
En recrutement
Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States
Site Public Contact, Contact, 855-776-0015
Wendy Allen-Rhoades, Investigateur principal
En recrutement
Mississippi
University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States
Site Public Contact, Contact, 601-815-6700
Betty L. Herrington, Investigateur principal
En recrutement
Missouri
Children's Mercy Hospitals and Clinics, Kansas City, Missouri, 64108, United States
Site Public Contact, Contact, 816-302-6808, [email protected]
Keith J. August, Investigateur principal
En recrutement
Cardinal Glennon Children's Medical Center, St Louis, Missouri, 63104, United States
Site Public Contact, Contact, 314-268-4000
William S. Ferguson, Investigateur principal
En recrutement
Washington University School of Medicine, St Louis, Missouri, 63110, United States
Site Public Contact, Contact, 800-600-3606, [email protected]
Amy Armstrong, Investigateur principal
En recrutement
Mercy Hospital Saint Louis, St Louis, Missouri, 63141, United States
Site Public Contact, Contact, 314-251-7066
Robin D. Hanson, Investigateur principal
En recrutement
Nebraska
Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, 68114, United States
Site Public Contact, Contact, 402-955-3949
Jill C. Beck, Investigateur principal
En recrutement
University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States
Site Public Contact, Contact, 402-559-6941, [email protected]
Jill C. Beck, Investigateur principal
En recrutement
Nevada
Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, 89135, United States
Site Public Contact, Contact, 702-384-0013, [email protected]
Alan K. Ikeda, Investigateur principal
En recrutement
Summerlin Hospital Medical Center, Las Vegas, Nevada, 89144, United States
Site Public Contact, Contact, 702-384-0013, [email protected]
Alan K. Ikeda, Investigateur principal
En recrutement
Renown Regional Medical Center, Reno, Nevada, 89502, United States
Site Public Contact, Contact, 702-384-0013, [email protected]
Alan K. Ikeda, Investigateur principal
En recrutement
New Hampshire
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, 03756, United States
Site Public Contact, Contact, 800-639-6918, [email protected]
Angela Ricci, Investigateur principal
En recrutement
New Jersey
Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States
Site Public Contact, Contact, 551-996-2897
Katharine Offer, Investigateur principal
En recrutement
Morristown Medical Center, Morristown, New Jersey, 07960, United States
Site Public Contact, Contact, 973-971-5900
Kathryn L. Laurie, Investigateur principal
En recrutement
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 08903, United States
Site Public Contact, Contact, 732-235-8675
Scott Moerdler, Investigateur principal
En recrutement
Newark Beth Israel Medical Center, Newark, New Jersey, 07112, United States
Site Public Contact, Contact, 973-926-7230, [email protected]
Teena Bhatla, Investigateur principal
En recrutement
New Mexico
University of New Mexico Cancer Center, Albuquerque, New Mexico, 87106, United States
Site Public Contact, Contact, 505-925-0348, [email protected]
Jessica M. Valdez, Investigateur principal
En recrutement
New York
Albany Medical Center, Albany, New York, 12208, United States
Site Public Contact, Contact, 518-262-5513
Lauren R. Weintraub, Investigateur principal
En recrutement
Roswell Park Cancer Institute, Buffalo, New York, 14263, United States
Site Public Contact, Contact, 800-767-9355, [email protected]
Ajay Gupta, Investigateur principal
En recrutement
The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, 11040, United States
Site Public Contact, Contact, 718-470-3460
Carolyn F. Levy, Investigateur principal
En recrutement
Mount Sinai Hospital, New York, New York, 10029, United States
Site Public Contact, Contact, 212-824-7309, [email protected]
Pamela R. Merola, Investigateur principal
En recrutement
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States
Site Public Contact, Contact, 212-342-5162, [email protected]
Nobuko Hijiya, Investigateur principal
En recrutement
Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States
Site Public Contact, Contact, 212-639-7592
Leonard H. Wexler, Investigateur principal
En recrutement
University of Rochester, Rochester, New York, 14642, United States
Site Public Contact, Contact, 585-275-5830
Rafi R. Kazi, Investigateur principal
En recrutement
State University of New York Upstate Medical University, Syracuse, New York, 13210, United States
Site Public Contact, Contact, 315-464-5476
Melanie A. Comito, Investigateur principal
En recrutement
Montefiore Medical Center - Moses Campus, The Bronx, New York, 10467, United States
Site Public Contact, Contact, 718-379-6866, [email protected]
Alice Lee, Investigateur principal
En recrutement
New York Medical College, Valhalla, New York, 10595, United States
Site Public Contact, Contact, 914-594-3794
Jessica C. Hochberg, Investigateur principal
En recrutement
North Carolina
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, 27599, United States
Site Public Contact, Contact, 877-668-0683, [email protected]
Thomas B. Alexander, Investigateur principal
En recrutement
Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, 28203, United States
Site Public Contact, Contact, 800-804-9376
Joel A. Kaplan, Investigateur principal
En recrutement
Novant Health Presbyterian Medical Center, Charlotte, North Carolina, 28204, United States
Site Public Contact, Contact, 980-201-6360, [email protected]
Jessica A. Bell, Investigateur principal
En recrutement
Duke University Medical Center, Durham, North Carolina, 27710, United States
Site Public Contact, Contact, 888-275-3853
Jessica M. Sun, Investigateur principal
En recrutement
East Carolina University, Greenville, North Carolina, 27834, United States
Site Public Contact, Contact, 252-744-1015, [email protected]
Andrea R. Whitfield, Investigateur principal
En recrutement
Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States
Site Public Contact, Contact, 336-713-6771
Sarah Supples, Investigateur principal
En recrutement
North Dakota
Sanford Broadway Medical Center, Fargo, North Dakota, 58122, United States
Site Public Contact, Contact, 701-323-5760, [email protected]
Samuel J. Milanovich, Investigateur principal
En recrutement
Ohio
Children's Hospital Medical Center of Akron, Akron, Ohio, 44308, United States
Site Public Contact, Contact, 330-543-3193
Erin Wright, Investigateur principal
En recrutement
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States
Site Public Contact, Contact, 513-636-2799, [email protected]
Joseph G. Pressey, Investigateur principal
En recrutement
Rainbow Babies and Childrens Hospital, Cleveland, Ohio, 44106, United States
Site Public Contact, Contact, 216-844-5437
Duncan S. Stearns, Investigateur principal
En recrutement
Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States
Site Public Contact, Contact, 866-223-8100, [email protected]
Matteo M. Trucco, Investigateur principal
En recrutement
Nationwide Children's Hospital, Columbus, Ohio, 43205, United States
Site Public Contact, Contact, 614-722-6039, [email protected]
Mark A. Ranalli, Investigateur principal
En recrutement
Dayton Children's Hospital, Dayton, Ohio, 45404, United States
Site Public Contact, Contact, 800-228-4055
Jordan M. Wright, Investigateur principal
En recrutement
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, 43606, United States
Site Public Contact, Contact, 419-824-1842, [email protected]
Jamie L. Dargart, Investigateur principal
En recrutement
Oklahoma
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States
Site Public Contact, Contact, 405-271-8777, [email protected]
Rene Y. McNall-Knapp, Investigateur principal
En recrutement
Oregon
Oregon Health and Science University, Portland, Oregon, 97239, United States
Site Public Contact, Contact, 503-494-1080, [email protected]
Katrina Winsnes, Investigateur principal
En recrutement
Pennsylvania
Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, 18103, United States
Site Public Contact, Contact, 610-402-9543, [email protected]
Jacob A. Troutman, Investigateur principal
En recrutement
Geisinger Medical Center, Danville, Pennsylvania, 17822, United States
Site Public Contact, Contact, 570-271-5251, [email protected]
Jagadeesh Ramdas, Investigateur principal
En recrutement
Penn State Children's Hospital, Hershey, Pennsylvania, 17033, United States
Site Public Contact, Contact, 717-531-6012
Lisa M. McGregor, Investigateur principal
En recrutement
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States
Site Public Contact, Contact, 267-425-5544, [email protected]
Naomi J. Balamuth, Investigateur principal
En recrutement
Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, 19134, United States
Site Public Contact, Contact, 215-427-8991
Gregory E. Halligan, Investigateur principal
En recrutement
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, 15224, United States
Site Public Contact, Contact, 412-692-8570, [email protected]
Jean M. Tersak, Investigateur principal
En recrutement
Rhode Island
Rhode Island Hospital, Providence, Rhode Island, 02903, United States
Site Public Contact, Contact, 401-444-1488
Bradley DeNardo, Investigateur principal
En recrutement
South Carolina
Prisma Health Richland Hospital, Columbia, South Carolina, 29203, United States
Site Public Contact, Contact, 864-522-4317, [email protected]
Stuart L. Cramer, Investigateur principal
En recrutement
BI-LO Charities Children's Cancer Center, Greenville, South Carolina, 29605, United States
Site Public Contact, Contact, 864-522-4317, [email protected]
Aniket Saha, Investigateur principal
En recrutement
South Dakota
Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, 57117-5134, United States
Site Public Contact, Contact, 605-312-3320, [email protected]
Kayelyn J. Wagner, Investigateur principal
En recrutement
Tennessee
East Tennessee Childrens Hospital, Knoxville, Tennessee, 37916, United States
Site Public Contact, Contact, 865-541-8266
Susan E. Spiller, Investigateur principal
En recrutement
Saint Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States
Site Public Contact, Contact, 888-226-4343, [email protected]
Alberto S. Pappo, Investigateur principal
En recrutement
The Children's Hospital at TriStar Centennial, Nashville, Tennessee, 37203, United States
Site Public Contact, Contact, 615-342-1919
Clinton M. Carroll, Investigateur principal
En recrutement
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, 37232, United States
Site Public Contact, Contact, 800-811-8480
Scott C. Borinstein, Investigateur principal
En recrutement
Texas
Dell Children's Medical Center of Central Texas, Austin, Texas, 78723, United States
Site Public Contact, Contact, 512-628-1902, [email protected]
Shannon M. Cohn, Investigateur principal
En recrutement
Driscoll Children's Hospital, Corpus Christi, Texas, 78411, United States
Site Public Contact, Contact, 361-694-5311, [email protected]
Nkechi I. Mba, Investigateur principal
En recrutement
Medical City Dallas Hospital, Dallas, Texas, 75230, United States
Site Public Contact, Contact, 972-566-5588
Maurizio L. Ghisoli, Investigateur principal
En recrutement
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States
Site Public Contact, Contact, 214-648-7097, [email protected]
Avanthi T. Shah, Investigateur principal
En recrutement
El Paso Children's Hospital, El Paso, Texas, 79905, United States
Site Public Contact, Contact, 915-298-5444, [email protected]
Benjamin Carcamo, Investigateur principal
En recrutement
Cook Children's Medical Center, Fort Worth, Texas, 76104, United States
Site Public Contact, Contact, 682-885-2103, [email protected]
Kelly L. Vallance, Investigateur principal
En recrutement
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, 77030, United States
Site Public Contact, Contact, 713-798-1354, [email protected]
Stephanie Fetzko, Investigateur principal
En recrutement
M D Anderson Cancer Center, Houston, Texas, 77030, United States
Site Public Contact, Contact, 877-632-6789, [email protected]
Najat C. Daw, Investigateur principal
En recrutement
Covenant Children's Hospital, Lubbock, Texas, 79410, United States
Site Public Contact, Contact, 806-725-8657, [email protected]
Kishor M. Bhende, Investigateur principal
En recrutement
UMC Cancer Center / UMC Health System, Lubbock, Texas, 79415, United States
Site Public Contact, Contact, 806-775-8590
Erin K. Barr, Investigateur principal
En recrutement
Children's Hospital of San Antonio, San Antonio, Texas, 78207, United States
Site Public Contact, Contact, 210-704-2894, [email protected]
Julie Voeller, Investigateur principal
En recrutement
Methodist Children's Hospital of South Texas, San Antonio, Texas, 78229, United States
Site Public Contact, Contact, 210-575-6240, [email protected]
Jose M. Esquilin, Investigateur principal
En recrutement
University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States
Site Public Contact, Contact, 210-450-3800, [email protected]
Aaron J. Sugalski, Investigateur principal
En recrutement
Scott and White Memorial Hospital, Temple, Texas, 76508, United States
Site Public Contact, Contact, 254-724-5407
Nicholas W. McGregor, Investigateur principal
En recrutement
Utah
Primary Children's Hospital, Salt Lake City, Utah, 84113, United States
Site Public Contact, Contact, 801-585-5270
Matthew Dietz, Investigateur principal
En recrutement
Virginia
University of Virginia Cancer Center, Charlottesville, Virginia, 22908, United States
Site Public Contact, Contact, 434-243-6303, [email protected]
Brian C. Belyea, Investigateur principal
En recrutement
Inova Fairfax Hospital, Falls Church, Virginia, 22042, United States
Site Public Contact, Contact, 703-208-6650, [email protected]
Robin Y. Dulman, Investigateur principal
En recrutement
Children's Hospital of The King's Daughters, Norfolk, Virginia, 23507, United States
Site Public Contact, Contact, 757-668-7243, [email protected]
Melissa S. Mark, Investigateur principal
En recrutement
VCU Massey Comprehensive Cancer Center, Richmond, Virginia, 23298, United States
Site Public Contact, Contact, 804-628-6430, [email protected]
Frances Austin, Investigateur principal
En recrutement
Carilion Children's, Roanoke, Virginia, 24014, United States
Site Public Contact, Contact, 540-266-6238, [email protected]
Erwood G. Edwards, Investigateur principal
En recrutement
Washington
Seattle Children's Hospital, Seattle, Washington, 98105, United States
Site Public Contact, Contact, 866-987-2000
Sarah E. Leary, Investigateur principal
En recrutement
Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, 99204, United States
Site Public Contact, Contact, 800-228-6618, [email protected]
Judy L. Felgenhauer, Investigateur principal
En recrutement
Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, 98405, United States
Site Public Contact, Contact, 253-403-1461, [email protected]
Robert G. Irwin, Investigateur principal
En recrutement
Madigan Army Medical Center, Tacoma, Washington, 98431, United States
Site Public Contact, Contact, 253-968-6144, [email protected]
Melissa A. Forouhar, Investigateur principal
En recrutement
West Virginia
West Virginia University Charleston Division, Charleston, West Virginia, 25304, United States
Site Public Contact, Contact, 304-388-9944
Mohamad H. Badawi, Investigateur principal
En recrutement
Wisconsin
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, 53792, United States
Site Public Contact, Contact, 800-622-8922, [email protected]
Margo L. Hoover-Regan, Investigateur principal
En recrutement
Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, 54449, United States
Suspendu
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, 53226, United States
Site Public Contact, Contact, 414-955-4727, [email protected]
Kerri Becktell, Investigateur principal
En recrutement
New South Wales
Sydney Children's Hospital, Randwick, New South Wales, 2031, Australia
Site Public Contact, Contact, (02) 9382-1721
Draga Barbaric, Investigateur principal
En recrutement
The Children's Hospital at Westmead, Westmead, New South Wales, 2145, Australia
Site Public Contact, Contact, 61-2-9845 1400
Bhavna Padhye, Investigateur principal
En recrutement
Western Australia
Perth Children's Hospital, Perth, Western Australia, 6009, Australia
Site Public Contact, Contact, [email protected]
Marianne B. Phillips, Investigateur principal
En recrutement
Auckland
Starship Children's Hospital, Grafton, Auckland, 1145, New Zealand
Site Public Contact, Contact, 0800 728 436
Mandy PohLui de Silva, Investigateur principal
En recrutement
Christchurch Hospital, Christchurch, 8011, New Zealand
Site Public Contact, Contact, 03 364 0640
Tristan Pettit, Investigateur principal
En recrutement